Table 2 Examples of power estimates
From: Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Hazard ratios | Death rate | PALOMA-2 trial | MONALEESA-2 trial | MONALEESA-7 trial | MONARCH-3 trial |
|---|---|---|---|---|---|
0.77 | 40% | 0.55 | 0.57 | 0.57 | 0.44 |
(15 months gain in median OS) | 60% | 0.73 | 0.74 | 0.74 | 0.60 |
80% | 0.84 | 0.85 | 0.85 | 0.72 | |
0.81 | 40% | 0.39 | 0.40 | 0.40 | 0.30 |
(12 months gain in median OS) | 60% | 0.54 | 0.56 | 0.56 | 0.42 |
80% | 0.66 | 0.68 | 0.68 | 0.53 | |
0.89 | 40% | 0.15 | 0.16 | 0.16 | 0.12 |
(6 months gain in median OS) | 60% | 0.20 | 0.21 | 0.21 | 0.16 |
80% | 0.25 | 0.27 | 0.27 | 0.20 | |
0.94 | 40% | 0.07 | 0.07 | 0.07 | 0.06 |
(3 months gain in median OS) | 60% | 0.09 | 0.09 | 0.09 | 0.07 |
80% | 0.10 | 0.11 | 0.11 | 0.08 |
